Cargando…

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition

Sorafenib, a multikinase inhibitor, is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, resistance to this regimen is frequently observed in clinical practice, and the molecular basis of this resistance remains largely unknown. Herein, the antitumor activi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Bo, Cheng, Jian-Wen, Hu, Jin-Wu, Li, Hong, Ma, Xiao-Lu, Tang, Wei-Guo, Sun, Yun-Fan, Guo, Wei, Huang, Ao, Zhou, Kai-Qian, Gao, Ping-Ting, Cao, Ya, Qiu, Shuang-Jian, Zhou, Jian, Fan, Jia, Yang, Xin-Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692625/ https://www.ncbi.nlm.nih.gov/pubmed/31417635 http://dx.doi.org/10.7150/jca.31448

Ejemplares similares

Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation
por: Dong, Shuying, et al.
Publicado: (2015)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016)

Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells
por: Xu, Gui-Li, et al.
Publicado: (2020)

Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma
por: Wang, Hongjun, et al.
Publicado: (2015)

linc-ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1-mediated epithelial-mesenchymal transition
por: Zhang, Yuanbiao, et al.
Publicado: (2021)

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Liao, Li-Zhu, et al.
Publicado: (2020)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019)

KPNA2 promotes migration and invasion in epithelial ovarian cancer cells by inducing epithelial-mesenchymal transition via Akt/GSK-3β/Snail activation
por: Huang, Long, et al.
Publicado: (2018)

HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer
por: Yang, Jian, et al.
Publicado: (2016)

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Wang, Shanshan, et al.
Publicado: (2023)

Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial–mesenchymal transition
por: He, Lu, et al.
Publicado: (2014)

Twist: A Regulator of Epithelial-Mesenchymal Transition in Lung Fibrosis
por: Pozharskaya, Veronika, et al.
Publicado: (2009)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

A novel epithelial–mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma
por: Shi, Yanlong, et al.
Publicado: (2022)

Protease-activated receptor-1 (PAR1) promotes epithelial-endothelial transition through Twist1 in hepatocellular carcinoma
por: Xiao, Ting, et al.
Publicado: (2018)

miR-214-3p inhibits epithelial-to-mesenchymal transition and metastasis of endometrial cancer cells by targeting TWIST1
por: Fang, Yuan-Yuan, et al.
Publicado: (2019)

Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1
por: Zhao, Xiu-lan, et al.
Publicado: (2011)

Mutant CFTR Drives TWIST1 mediated epithelial–mesenchymal transition
por: Quaresma, Margarida C., et al.
Publicado: (2020)

Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin
por: Dong, Qiongzhu, et al.
Publicado: (2016)

Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation
por: Zhang, Yong-Qu, et al.
Publicado: (2015)

SRC-1 and Twist1 are prognostic indicators of liver cancer and are associated with cell viability, invasion, migration and epithelial-mesenchymal transformation of hepatocellular carcinoma cells
por: Zhao, Peng-Wei, et al.
Publicado: (2020)

Nuclear import of prototype foamy virus transactivator Bel1 is mediated by KPNA1, KPNA6 and KPNA7
por: Duan, Jihui, et al.
Publicado: (2017)

Nuclear import of prototype foamy virus transactivator Bel1 is mediated by KPNA1, KPNA6 and KPNA7
por: Duan, Jihui, et al.
Publicado: (2016)

Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions
por: Guo, Fei, et al.
Publicado: (2014)

Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition
por: Fouquet, Grégory, et al.
Publicado: (2022)

LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells: LIMT contributes to sorafenib chemoresistance in HCC
por: Sun, Jing, et al.
Publicado: (2021)

CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5‐LSD1‐NF‐κB oncogenic signaling
por: Hu, Bo, et al.
Publicado: (2020)

Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition
por: Khan, Md. Asaduzzaman, et al.
Publicado: (2015)

Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition
por: Malouf, Gabriel G, et al.
Publicado: (2013)

NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells
por: Hu, Bo, et al.
Publicado: (2018)

circSMAD2 inhibits the epithelial–mesenchymal transition by targeting miR-629 in hepatocellular carcinoma
por: Zhang, Xianwei, et al.
Publicado: (2018)

SOX5 promotes cell invasion and metastasis via activation of Twist-mediated epithelial–mesenchymal transition in gastric cancer
por: You, Jianxiong, et al.
Publicado: (2019)

MTF2 Induces Epithelial-Mesenchymal Transition and Progression of Hepatocellular Carcinoma by Transcriptionally Activating Snail
por: Wu, Tian-Tian, et al.
Publicado: (2019)

Inhibitor of Differentiation 1 (ID1) Facilitates the Efficacy of Sorafenib in Non-Small Cell Lung Cancer Cells through Suppressing Epithelial to Mesenchymal Transition
por: Zhao, Yu-xiao, et al.
Publicado: (2020)

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer: COM33 sensitizes ovarian cancer to carboplatin
por: Zhou, Zhiyang, et al.
Publicado: (2022)

Restoration of FBP1 suppressed Snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma
por: Liu, Gao-Min, et al.
Publicado: (2018)

Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells
por: Dong, Jiejie, et al.
Publicado: (2017)

Fuzheng Huayu Recipe Ameliorates Liver Fibrosis by Restoring Balance between Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Hepatic Stellate Cells
por: Pan, Qin, et al.
Publicado: (2015)

Reversal of TGF-β-induced epithelial–mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor
por: Modi, Siddharth J., et al.
Publicado: (2021)

KIAA1429 mediates epithelial mesenchymal transition in sorafenib‐resistant hepatocellular carcinoma through m6A methylation modification
por: Kuang, Ye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_88bs3htp1of0qgcg76o1b7pdrq